The pharmaceutical company Moderna intends to bring its Covid vaccine to Latin America, including Brazil among the possible destinations, in addition to Mexico, Colombia and Argentina.
For this, the company made a partnership with the Latin American pharmaceutical group Adium Pharma, which will be responsible for the distribution of immunizers.
In Brazil, the group is represented by Zodiac Produtos Farmacêuticos.
In a note on Tuesday (22), Zodiac says it will collaborate with Moderna “in the processes of registrations with regulatory agencies, support for pharmacovigilance activities, continuing medical education, government affairs to ensure access and availability of Spikevax [nome da vacina] in Brazil”.
Moderna’s vaccine is not yet authorized for use in Brazil. There is no information about the timetable for entering the application for use with Anvisa (National Health Surveillance Agency). So far, only vaccines from AstraZeneca/Oxford, Pfizer, Janssen and Coronavac (from China’s Sinovac in partnership with Butantan) are authorized for use in the country.
Moderna claims to have an agreement to distribute its vaccine in 45 countries.
Moderna’s immunizer, like Pfizer’s, uses mRNA (messenger RNA) as a vaccine platform.
In general terms, this type of platform teaches our body to build the coronavirus spike protein, which is used by the virus to invade our cells. In this way, the immune system already has previous contact with the “foreign body” and, in case of contamination, the body already knows how to fight the Sars-CoV-2 infection.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.
